Carlos Marugán
A5010019236- Microtubule and mitosis dynamics
- Estrogen and related hormone effects
- 14-3-3 protein interactions
- Cancer-related Molecular Pathways
- Photosynthetic Processes and Mechanisms
- Advanced Breast Cancer Therapies
- Cancer, Hypoxia, and Metabolism
- Ubiquitin and proteasome pathways
- Genomics and Chromatin Dynamics
- Distributed and Parallel Computing Systems
- Hippo pathway signaling and YAP/TAZ
- Ferrocene Chemistry and Applications
- HER2/EGFR in Cancer Research
- Growth Hormone and Insulin-like Growth Factors
- Plant nutrient uptake and metabolism
- Cancer Treatment and Pharmacology
- Brain Metastases and Treatment
- Prostate Cancer Treatment and Research
- Lung Cancer Research Studies
- PARP inhibition in cancer therapy
- Gene Regulatory Network Analysis
- PI3K/AKT/mTOR signaling in cancer
Eli Lilly (Spain)
2016-2024
Instituto de Investigaciones Biomédicas Sols-Morreale
2023-2024
Universidad Autónoma de Madrid
2023-2024
Eli Lilly (United States)
2021
Spanish National Cancer Research Centre
2015-2016
Loss-of-function mutations in the retinoblastoma gene RB1 are common several treatment-refractory cancers such as small-cell lung cancer and triple-negative breast cancer. To identify drugs synthetic lethal with mutation (RB1 mut), we tested 36 cell-cycle inhibitors using a cell panel profiling approach optimized to discern cytotoxic from cytostatic effects. Inhibitors of Aurora kinases AURKA AURKB showed strongest association this assay. LY3295668, an inhibitor over 1,000-fold selectivity...
Abstract Although Aurora A, B, and C kinases share high sequence similarity, especially within the kinase domain, they function distinctly in cell-cycle progression. A depletion primarily leads to mitotic spindle formation defects consequently prometaphase arrest, whereas B/C inactivation induces polyploidy from cytokinesis failure. phenotypes are also epistatic those of such that concomitant or all isoforms by nonisoform–selective inhibitors, demonstrates B/C-dominant failure phenotypes....
<p>In vivo single agent imlunestrant efficacy in ESR1-mutant and wild type xenograft PDX breast cancer models.</p>
<div>Abstract<p>Targeting of the estrogen receptor (ER) by antiestrogens is standard care for patients with ER<sup>+</sup> HER2<sup>−</sup> advanced/metastatic breast cancer. Although that degrade ERα (fulvestrant) or block production (aromatase inhibitors) have improved patient outcomes, clinically important challenges remain related to drug administration, limited bioavailability, lack brain exposure, and acquired resistance due ESR1 mutations. These...
<p>Statistical survival analysis and body weight change in MCF-7 intracranial model treated with imlunestrant or other SERDs.</p>
<p>Biochemical and in vitro characterization of imlunestrant.</p>
<p>In vivo imlunestrant efficacy alone and in combination with abemaciclib, alpelisib, everolimus CDX breast cancer models.</p>
<p>Imlunestrant, elacestrant, and fulvestrant mediated ER degradation, PGR gene inhibition cell proliferation in T-47D parental ESR1-Y537N cells.</p>
<p>Imlunestrant PK/PD and uterotrophic activity.</p>
<p>Statistical analysis of imlunestrant and fulvestrant efficacy alone in combination with abemaciclib, alpelisib, everolimus ESR1-wild type mutant xenograft PDX breast cancer models</p>
<p>In vivo single agent imlunestrant efficacy in ESR1-mutant and wild type xenograft PDX breast cancer models.</p>
<p>Biochemical and in vitro characterization of imlunestrant.</p>
<p>Imlunestrant, elacestrant, and fulvestrant mediated ER degradation, PGR gene inhibition cell proliferation in T-47D parental ESR1-Y537N cells.</p>
<p>Statistical survival analysis and body weight change in MCF-7 intracranial model treated with imlunestrant or other SERDs.</p>
<p>Statistical analysis of imlunestrant and fulvestrant efficacy alone in combination with abemaciclib, alpelisib, everolimus ESR1-wild type mutant xenograft PDX breast cancer models</p>
<p>In vivo imlunestrant efficacy alone and in combination with abemaciclib, alpelisib, everolimus CDX breast cancer models.</p>
<p>Imlunestrant PK/PD and uterotrophic activity.</p>
Polo‐like kinase 1 (PLK1) is a serine/threonine that plays multiple and essential roles during the cell division cycle. Its inhibition in cultured cells leads to severe mitotic aberrancies death. Whereas previous reports suggested Plk1 depletion mice non‐mitotic arrest early embryos, we show here bi‐allelic certainly results embryonic lethality due extensive aberrations at morula stage, including multi‐ mono‐polar spindles, impaired chromosome segregation cytokinesis failure. In addition,...
// Raquel Torres-Guzmán 1 , Maria Patricia Ganado Cecilia Mur Carlos Marugan Carmen Baquero Yanzhu Yang 2 Yi Zeng Huimin Bian Jian Du Alfonso de Dios Oscar Puig 3 and María José Lallena Discovery Chemistry Research Technology, Eli Lilly Company, Madrid, Spain Indianapolis, IN 46225, USA New York, NY 10016, Correspondence to: Lallena, email: lallena_maria_jose@lilly.com Keywords: abemaciclib; breast cancer; cell lines; CDK4/6; continuous dosing Received: March 17,...
Chromosomal instability (CIN) is a hallmark of cancer aggressiveness, providing genetic plasticity and tumor heterogeneity that allows the to evolve adapt stress conditions. CIN considered therapeutic biomarker because healthy cells do not exhibit CIN. Despite recent efforts identify strategies related CIN, results obtained have been very limited. characterized by signature where collection genes, mostly mitotic regulators, are overexpressed in CIN‐positive tumors, aggressiveness poor...
Targeting of the estrogen receptor (ER) by anti-estrogens is standard-of-care for patients with ER+ HER2- advanced/metastatic breast cancer. While that degrade ERα (fulvestrant) or block production (aromatase inhibitors) have improved patient outcomes, clinically important challenges remain related to drug administration, limited bioavailability, lack brain exposure, and acquired resistance due ESR1 mutations. These limitations indicate a need more robust ER-targeted therapies. Here, we...